2021年1月14日,

對預測疾病最早2017年11月30日新聞稿信諾,GIS戰略投資,赫姆,Hikma Ventures Maywic,默克全球健康行動計劃基金,和維護科學賭Prognos早些時候推動改革醫療保健的決策,改善病人的健康和降低成本紐約,11月30日,2017(全球通訊社)——Prognos革新者在將人工智能(AI)應用於臨床實驗室診斷,已完成2050萬美元的C係列一輪融資,使該公司的總資金4200萬美元。投資者包括信諾、GIS戰略投資(衛報人壽保險公司的風險投資部門),赫姆,Hikma Ventures Maywic,默克全球衛生創新基金(GHI),維護科學。支持驗證Prognos市場的領導地位是唯一醫療AI公司能夠提供前瞻性的基於實驗室和診斷記錄和實時的見解。Prognos的七年的基礎之上進行構建,C係列融資將幫助公司滿足具有高度針對性的生命科學和支付市場的增長目標。Prognos的解決方案使患者的早期識別可以受益於增強治療決策、風險管理和質量改進。公司目前正在幫助25生命科學品牌找到並把適當的病人,同時構建一個支付市場的足跡。”係列Prognos, C是一個專注和自律努力建立我們的成功業務規模正如我們前麵預測疾病的追求我們的使命驅動對病人有更好的效果,“Sundeep Bhan說Prognos的創始人和首席執行官。“我們認為這一輪的信任票醫療行業專家和全球投資公司了解的空間,相信Prognos可以繼續領導提供早期的見解提供更好的病人護理和更低的成本。“新資金將用於擴大Prognos AI功能,新市場,銷售和營銷努力。到目前為止,Prognos建立了連接網絡在美國最大的實驗室,processed and analyzed over 13 billion lab records for more than 180 million patients, and developed 1,000+ proprietary machine learning-enabled algorithms across 50 conditions, such as diabetes, asthma, and non-small cell lung cancer, for the lab data management and analysis. Within the last year, Prognos has also bolstered its leadership team with the additions of Chief Operating Officer Lisa Kerber, Chief Commercial Officer Stephen Silvestro and Chief Data Scientist Fernando Schwartz, Ph.D. “Healthcare AI and the right kind of big data, such as lab and diagnostics data driving clinical decision-making, has the potential to enable us to identify patients more likely to benefit from a particular therapy,” said Joe Volpe, Managing Director, Merck GHI Fund. “This round continues our investment into Prognos, the healthcare AI company that has demonstrated its capability to transform how the Life Sciences industry does business, now and in the future.” Global health service company Cigna has been working with Prognos to use lab data and analytics to improve health engagement among its Individual and Family Plan customers. “AI is a game changer in healthcare risk management,” said Craig Cimini, VP Strategy and Business Development at Cigna. “We have seen Prognos’ capabilities first-hand and believe health plans will greatly benefit from integrating real-time lab and diagnostics data intelligence to refine their approaches to risk adjustment, clinical quality, and care management.” About Prognos Prognos is a healthcare AI company focused on predicting disease to drive decisions earlier in healthcare in collaboration with payers, Life Sciences and diagnostics companies. The Prognos Registry is the largest source of clinical diagnostics information in 50 disease areas, with over 13B medical records for 180M patients. Prognos has 1000 extensive proprietary and learning clinical algorithms to enable earlier patient identification for enhanced treatment decision-making, risk management and quality improvement. The company is supported by a $42M investment from Safeguard Scientifics, Inc. (NYSE: SFE ), Merck Global Health Innovation Fund (GHIF), Cigna (CI), GIS Strategic Ventures, Hikma Ventures, Hermed Capital, and Maywic Select Investments. For more information, visit www.prognos.wpengine.com .